UK – NICE recommends Lenvima for advanced liver cancer

The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima (lenvatinib), a potentially life-extending treatment for advanced hepatocellular carcinoma (HCC) in adults with Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

The drug will be available for people with advanced liver cancer, whose disease cannot be treated surgically but whose liver is well-functioning, and works by slowing down the growth and spread of cancer cells by cutting off the blood supply that keeps cancer cells growing.

The appraisal made by NICE, made on the back of data showing that patients experienced a median overall survival of 13.6 months compared to 12.3 months with alternative treatment Nexavar, while median PFS was 7.3 months versus 3.6 months, respectively, will benefit around 900 hundred patients each year…